Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Fig 5
Determination of the sensitivity of ARQ 092 and ARQ 751 with different cancer cell types.
Plots of cancer type versus drug sensitivity and number of cell lines per cancer type were prepared for ARQ 092 (left panel) and ARQ 751 (right panel).